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abstract
PURPOSE Circulating tumor DNA (ctDNA) sequencing provides aminimally invasive method for tumor molecular
stratiﬁcation. Commercial ctDNA sequencing is increasingly used in the clinic, but its accuracy in metastatic
prostate cancer is untested. We compared the commercial Guardant360 ctDNA test against an academic
sequencing approach for proﬁling metastatic prostate cancer.
PATIENTS AND METHODS Plasma cell-free DNA was collected between September 2016 and April 2018 from 24
patients with clinically progressive metastatic prostate cancer representing a range of clinical scenarios. Each
sample was analyzed using Guardant360 and a research panel encompassing 73 prostate cancer genes.
Concordance of somatic mutation and copy number calls was evaluated between the two approaches.
RESULTS Targeted sequencing independently conﬁrmed 94% of somatic mutations identiﬁed by Guardant360
at an allele fraction greater than 1%. AR ampliﬁcations and mutations were detected with high concordance in
14 patients, with only three discordant subclonal mutations at an allele fraction lower than 0.5%. Many somatic
mutations identiﬁed by Guardant360 at an allele fraction lower than 1% seemed to represent subclonal
passenger events or non–prostate-derived clones. Most of the non-AR gene ampliﬁcations reported by
Guardant360 represented single copy gains. The research approach detected several clinically relevant DNA
repair gene alterations not reported by Guardant360, including four germline truncatingBRCA2/ATMmutations,
two somatic ATM stop gain mutations, one BRCA2 biallelic deletion, 11 BRCA2 stop gain reversal mutations in
a patient treated with olaparib, and a hypermutator phenotype in a patient sample with 42 mutations per
megabase.
CONCLUSION Guardant360 accurately identiﬁes somatic ctDNA mutations in patients with metastatic prostate
cancer, but low allele frequency mutations should be interpreted with caution. Test utility in metastatic prostate
cancer is currently limited by the lack of reporting on actionable deletions, rearrangements, and germline
mutations.
JCO Precis Oncol. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Molecular stratiﬁcation is poised to guide treatment of
metastatic prostate cancer (mPC), but tissue biopsies
are difﬁcult to acquire, because many patients lack
soft tissue metastases. Fortunately, circulating tumor
DNA (ctDNA) can be detected in peripheral blood
cell–free DNA (cfDNA) from most patients with pro-
gressive disease.1-4 Numerous research, industry, and
commercial cfDNA sequencing assays have arisen,
each aiming to provide a practical alternative to met-
astatic tissue biopsy for tumor molecular stratiﬁcation.
Unlike many other solid cancers, where ctDNA assays
can rely on detection of recurrent clinically relevant
mutations,5 mPC is characterized by a low mutation
rate and high prevalence of large structural rear-
rangements, including deletions and translocations.6
Furthermore, up to 30% of patients with mPC harbor
deleterious germline and/or somatic defects in DNA
damage repair genes, such as BRCA2.7
The Clinical Laboratory Improvement Amendments–
certiﬁed Guardant360 ctDNA test (Guardant Health,
Redwood City, CA) identiﬁes single-nucleotide variants
(SNVs) in 73 genes, insertions/deletions (indels) in 23
genes, copy number ampliﬁcations (CNAs) in 18
genes, and gene fusions in six genes. It is widely used
for characterization of mPC and other solid cancers.8
Recently, low congruency was reported between
mPC samples submitted for parallel testing with
Guardant360 and another commercial ctDNA assay,
PlasmaSELECT (Personal Genome Diagnostics, Bal-
timore, MD).9 A separate study examining breast
and other solid cancers subjected matched patient
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specimens to Guardant360 ctDNA testing and Founda-
tionOne (Foundation Medicine, Cambridge, MA) tumor
tissue testing and also found high discordance, particularly
for mutations reported at allele frequencies lower than 1%.
10 Together, these results raise signiﬁcant concerns about
the accuracy of ctDNA testing in precision oncology and are
consistent with recent consensus statements on in-
sufﬁcient evidence of clinical validity for ctDNA assays in
advanced cancer11 and lack of support for routine ctDNA
testing in mPC.12
Given the increasing use of commercial ctDNA testing, we
sought to assess the strengths and limitations of Guardant360
in mPC. We previously demonstrated high concordance for
somatic alterations detected in ctDNA and matched meta-
static tissue using a PC-speciﬁc targeted sequencing ap-
proach applied in a research setting.13 Therefore, in the study
reported here, we performed a blinded analysis of 24 cfDNA
samples subjected to Guardant360 testing and our academic
cfDNA sequencing approach.
PATIENTS AND METHODS
Blood Collection and Guardant360 Testing
Peripheral venous blood was collected between September
2016 and April 2018 from 24 patients with progressive
castration-resistant mPC (Data Supplement). Blood was
collected in two 10-cc Streck tubes following Guardant
Health standard collection protocol and shipped for testing
at Guardant Health. Guardant360 uses digital sequencing
to detect SNVs, indels, CNAs, and fusions in select exons
and genes from cfDNA. All genomic alterations reported by
Guardant360 in each of the 24 patients with mPC were
used in this study. Raw Guardant360 sequencing data
were not available for bioinformatic analysis, and there was
no research agreement with Guardant Health.
Matched same-day samples from the 24 patients with mPC
sent for Guardant360 testing were subjected to targeted
cfDNA and WBC sequencing using a previously published
academic approach (the Vancouver panel).2,13 Targeted
cfDNA and WBC sequencing and data analysis were
performed and ﬁnalized before examination of Guar-
dant360 reports. Approval for this study was granted by the
Tulane University Institutional Review Board (certiﬁcate
M0600) and the University of British Columbia Clinical
Research Ethics Board (certiﬁcate H18-00944). The study
was conducted in accordance with the Declaration of
Helsinki, and written informed consent was obtained from
all participants before enrollment.
Sequence Alignment and Quality Control
Paired-end reads (from the Vancouver panel) were aligned
against an hg38 reference genome using Bowtie (version 2.
3.0).14 For WBC samples, duplicate reads were marked
using samblaster (version 0.1.24).15 For cfDNA samples that
carried 4-bp unique molecular identiﬁers, reads were
marked as duplicates if they were aligned to the same po-
sition and their 4-bp uniquemolecular identiﬁers had at least
three identical bases. Adapters in read 3′ ends were trimmed
in paired mode using cutadapt (version 1.11).16 Low-quality
read tails (smoothed baseq, 30) were trimmed using an in-
house algorithm. Per-base read coverages in target regions
were counted using bedtools (version 2.25.0).17 cfDNA/WBC
sample pairings were veriﬁed based on SNP genotypes.
Analysis of Somatic Mutations
Somatic mutations were called in cfDNA samples by
searching for variants with at least eight supporting reads
and a mutant allele fraction (AF) of at least 0.5%. The AF
was required to be at least 20 times higher than the average
AF across all WBC samples and at least three times higher
than the AF in the paired WBC sample. The paired WBC
sample had to have at least 20 reads covering the position.
For base substitutions, the average mapping quality of
mutation supporting reads was required to be at least 10,
CONTEXT
Key Objective
To evaluate a commercial circulating tumor (ctDNA) test by comparing it against a prostate cancer–speciﬁc research panel in
matched same-day plasma samples from men with metastatic prostate cancer.
Knowledge Generated
High concordance between the approaches was observed for AR gene copy number calls and somatic mutations at an allele
fraction greater than 1%. Most low allele fraction mutations reported by the commercial test seemed to represent subclonal
passenger mutations or non–prostate-derived mutations. The commercial test did not report several clinically actionable
DNA repair defects, including BRCA2 somatic homozygous deletions, structural rearrangements, and germline truncating
mutations.
Relevance
Our results suggest that clinicians should use caution when interpreting commercial ctDNA test results, particularly in the
context of low allele fraction mutations. Test utility in prostate cancer is limited by the lack of reporting on germline
mutations, somatic deletions, and structural variants.
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and the average distance of the mutant allele from the
nearest read end was required to be at least 15 bases. Our
mutation analysis pipeline was previously validated in
matched tissue-cfDNA cohorts13,18 and in dilution series
experiments.2 Protein-level consequences of variants were
predicted using ANNOVAR.19 ctDNA fractions were esti-
mated based on somatic mutation AFs as previously de-
scribed.2
Mutations were considered subclonal if their AF was less
than 0.25 times the ctDNA fraction (for autosomes) or less
than 0.5 times the ctDNA fraction (for chromosome X). This
conservative threshold was determined by halving the
expected AF for truncal mutations.
Two TP53 missense mutations in the cohort had an AF
greater than 1% in cfDNA and a similar AF in the matched
WBC sample. Because these mutations likely originated
from an expanded mutant WBC clone (clonal hemato-
poiesis), we rejected them as somatic PC mutations. One of
these mutations (a TP53 p.R273H missense mutation in
patient 5) was reported by Guardant360 and is included in
Figures 1A and 1B and the Data Supplement.
Analysis of Deleterious Germline Variants
Germline variants were called in WBC samples by
searching for variants with an alternate AF of at least 15%
and at least eight supporting reads. Germline variants with
a population allele frequency of 0.5% or higher in the
KAVIAR (Known Variants) or ExAC (Exome Aggregation
Consortium) database were discarded. Protein-level con-
sequences of variants were predicted using ANNOVAR.19
Copy number Calling
Reads were counted in all target regions using bedtools
(version 2.25.0).17 A control cfDNA sample from a healthy
volunteer was used as a reference for GC correction. GC
fraction was calculated for all target regions, and a scatter
plot was created for each sample showing target regions as
dots, with coverage log ratio relative to golden reference on
the y-axis and GC fraction on the x-axis. Loess regression
was applied to the scatter plot to normalize GC bias across
all samples. After GC correction, a median reference proﬁle
representing noncancerous cfDNA was constructed based
on 138 cfDNA samples with no detectable somatic mu-
tations or ampliﬁcations. The ﬁnal coverage log ratio for
each gene was calculated as the median coverage log ratio
of all target regions inside the gene. Our copy number
analysis pipeline was previously validated in a matched
tissue-cfDNA cohort.13
A deletion was called for a gene when the coverage log ratio
was −0.3 or lower. A gain was called for a gene when the
coverage log ratio was 0.3 or higher. These conservative
thresholds were determined empirically by studying a plot
of coverage log ratios and heterozygous SNP AFs in
samples with and without detectable ctDNA.
Categorization of Putative PC Driver Alterations
The following somatic mutations detected in the cohort were
considered putative PC drivers: TP53 missense and trun-
cating mutations; AR missense mutations in amino
acids 702, 742, 875, 878, and 893; AKT1 p.E17K mis-
sensemutations; APC truncatingmutations;BRAFmissense
mutations in amino acids 600 and 601; PTEN missense
mutations in amino acid 35; PIK3CA missense mutations in
amino acids 378, 391, and 1047;ATM truncatingmutations;
CTNNB1 missense mutations in amino acids 32 to 45; and
RB1 truncating mutations and missense mutations in amino
acid 661. Putative driver mutations were determined from
review of recently published large castration-resistant mPC
sequencing studies.6,20,21
Analysis of Serial Blood Collections
In addition to the matched 24 same-day samples subjected
to Guardant360 testing and Vancouver panel sequencing,
Guardant360 reports were available for an additional 86
blood collections from the same patients collected between
August 2015 and July 2018. Note that throughout the
course of the study time period, three versions of the
Guardant360 assay (68-, 70-, and 73-gene panels) were
used, with expanding coverage of genes and alterations. All
somatic mutations identiﬁed as discordant in this study
were conﬁrmed to have been tested with the Guardant360
73-gene panel.
RESULTS
Concordance of Somatic Mutation Calls
Our objective was to compare the Guardant360 test against
a PC-speciﬁc ctDNA research assay (Vancouver panel) that
identiﬁes SNVs, indels, ampliﬁcations, deletions, and
rearrangements in the exonic regions of 73 mPC-relevant
genes (Data Supplement).2,13,22 Between September 2016
and April 2018, we sent plasma from 24 patients with
clinically progressive mPC for Guardant360 testing and
performed targeted sequencing on matched same-day
samples using the Vancouver panel (median depth,
1,435×; data deposited to European Genome-Phenome
Archive under accession EGAS00001003352; Data Sup-
plement). Four patients had no detectable ctDNA according
to both assays. Across the remaining 20 patients, ctDNA
fractions estimated by the Vancouver panel ranged be-
tween undetectable (, 2%) and 80% (median, 23%; Data
Supplement).
Focusing on 26 genes covered by both approaches, 30
(94%) of 32 somatic mutations identiﬁed by Guardant360
with an AF greater than 1% were independently conﬁrmed
by the Vancouver panel (Figs 1A and 1B; Data Supple-
ment). Of the two discordant mutations, one was also found
in matched WBCs, and one had a low AF (0.8%) in our
analysis. Guardant360 also reported 28 somatic mutations
with an AF lower than 1%; previous reports have expressed
concern regarding AFs below this threshold.10 We found
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supporting reads for 24 (86%) of these mutations in cfDNA,
but nine of the mutations were found at a similar AF in
matched WBCs (which are not analyzed by Guardant360;
Figs 1A and 1B). Across all Guardant360 panel genes, 81%
of mutations with an AF greater than 1% had a putative
driver role in PC, compared with 41% of mutations with an
AF lower than 1% (Fisher’s exact test P , .001). Fur-
thermore, 82% of mutations with an AF lower than 1%were
found to be subclonal (Figs 1A and 1B; criteria described in
Patients and Methods). To explore further, we examined
serial Guardant360 test results from the same patients and
found that 96% of mutations detected at an AF lower than
1% did not reach an AF greater than 2% at any time point
(Fig 1C) and did not track with overall ctDNA fraction (Data
Supplement). These data suggest that many low AF mu-
tations identiﬁed by Guardant360 represent subclonal
passenger events or rare somatic clones of nonprostate
origin.
Guardant360 did not report seven of 39 somatic mutations
identiﬁed by the Vancouver panel at allele fractions be-
tween 6% and 14% (median, 10%; Data Supplement). The
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FIG 1. Concordance of somatic circulating tumor DNA mutation calls between Guardant360 and the Vancouver panel. Allele fractions of somatic mutations
based on the two assays: mutations with allele fraction of (A) 1% or greater and (B) lower than 1%. Known prostate cancer driver mutations are shown in blue;
other mutations in red. Bar plot below shows allele fraction inmatchedWBC samples. Mutations were labeled as subclonal if their allele fraction was less than
half the allele fraction expected for truncal mutations (described in Patients and Methods). It is plausible that some mutations labeled as subclonal had
a nonprostate origin. (C) Plot showing all mutations (dots) identiﬁed by Guardant360 in the cell-free DNA (cfDNA) time points that were also analyzed with the
Vancouver panel, grouped by allele fraction. Position along x-axis indicates the highest allele fraction that those mutations reached in other time points
analyzed by Guardant360. (D) Bar plot showing the total number of somatic mutations called by the Vancouver panel in 16 cfDNA samples with detectable
mutations. Patient 6 displays a hypermutation signature enriched for somatic CG.TG transitions and insertions/deletions, consistent with an underlying
mismatch repair defect.
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Vancouver panel also detected a high somatic mutation
burden (42 mutations per Mb) in patient 6 (Fig 1D), ac-
companied by MSH2 and MSH6 monoallelic losses.
Guardant360 does not report silent mutations or total
mutation burden. This patient had a complete remission
(9months at last follow-up) after pembrolizumab treatment.
Sensitivity Toward Somatic Changes in AR
The AR gene is altered in most treatment-resistant mPCs,
and AR status is associated with therapy response.1,2,6,23 In
this cohort, AR ampliﬁcations were identiﬁed in 11 of 24
patients, with perfect concordance between assays. So-
matic hotspot mutations in the androgen receptor (AR)
ligand-binding domain were also highly concordant, except
for three ARmutations detected by Guardant at an AF lower
than 0.5% (Fig 2A). These mutations had supporting reads
in our assay and were likely subclonal based on the pres-
ence of other mutations at higher AFs (Data Supplement).
Guardant360 does not report structural variants within the
AR gene. We identiﬁed two patients with AR ligand-binding
domain rearrangements predicted to yield a constitutively
active AR protein (Fig 2B).24
Identiﬁcation of Actionable DNA Repair Gene Alterations
Deleterious alterations in homologous recombination repair
genes are associated with response to poly (ADP-ribose)
polymerase (PARP) inhibitors and platinum-based che-
motherapy.7,25 The Vancouver panel identiﬁed six patients
with homologous recombination repair defects: four pa-
tients with a germline BRCA2 or ATM truncating mutation
(independently veriﬁed by commercial germline testing),
two patients with somatic ATM stop gain mutations, and
one patient with a somaticBRCA2 biallelic deletion (Figs 3A
and 3B). Guardant360 does not report germline mutations
or somatic copy number losses and surprisingly did not
report the two somatic ATM stop gain mutations. Notably,
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patient 17 was sampled after olaparib resistance in March
2018, and his cfDNA revealed 11 cancer cell populations
with somatic deletions or mutations reversing the germline
BRCA2 stop gain (Fig 3C).26 These alterations were not
reported by Guardant360, likely because it only reports
short indels.
Concordance of Gene Ampliﬁcation Calls
Ampliﬁcation of chromosome 7 genes MET, BRAF, and
CDK6 is rare in mPC, although low-level gain of chromo-
some 7 is common.6,21 MET, BRAF, and/or CDK6 was
reported ampliﬁed by Guardant360 in 13 patients. Our
analysis supported the presence of chromosome 7 single
copy gain in many of these patients (Fig 4A). Guardant360
additionally reported 12 ampliﬁcations in PIK3CA, CCND1,
and MYC, nine of which showed evidence consistent with
single copy gain. Only 11 of 40 reported non-AR ampliﬁ-
cations displayed evidence for more than a single copy gain
(Fig 4B). Guardant360 also reported 11 ampliﬁcations in
genes EGFR, PDGFRA, KIT, and FGFR1, which are rarely
altered in tissue-based mPC studies6 and are not assessed
by the Vancouver panel.
Guardant360 does not search for alterations in mPC genes
SPOP, CDK12, PIK3R1, FOXA1,MSH2,MSH6, TMPRSS2,
and ERG and does not report large somatic deletions or
complex structural variants in any genes. In total, we
identiﬁed potentially clinically relevant alterations that were
not reported by Guardant360 in 12 of 24 patients, including
a TP53 inactivating rearrangement, a CDKN1B biallelic
deletion, intragenic AR rearrangements in two patients,
three SPOP mutations, and DNA repair defects in seven
patients (Data Supplement).
DISCUSSION
The Guardant360 commercial ctDNA assay has improved
access to genomic testing across academic and non-
academic practitioners, especially in settings where tissue
biopsy is not feasible. As with any narrow pan-cancer assay,
there are compromises for individual cancer types.
Overall, we found excellent concordance between Guar-
dant360 and the Vancouver PC panel for high AF somatic
mutations. Guardant360 also exhibited high sensitivity for
low AF (, 1%) mutations, although our results suggest
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these mutations must be interpreted with caution. First,
a vast majority of these mutations were subclonal and
therefore potentially poor biomarkers for therapies aiming
at broad antitumor effect, although they may still be of
relevance for detecting emerging resistant clones. Second,
low AF mutations were more likely to have features con-
sistent with passenger status and therefore less relevance
to therapy resistance or response. Third, approximately one
third of low AF mutations had a similar level of read support
in the WBC fraction, suggestive of a clonal hematopoietic
origin. It is well established that elderly populations such as
those affected by PC have a high prevalence of clonal
hematopoiesis.27,28 Indeed, a recent study of cfDNA from
217 patients with mPC suggested that 15% would have
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the Vancouver panel) of AR compared with six other genes. Copy numbers were estimated based on sequencing coverage log ratio and circulating
tumor (ctDNA) fraction (described in Patients and Methods) and represent the average gene copy numbers in ctDNA-shedding cancer cells. Circle
size represents the estimated ctDNA fraction of a sample. (B) Sequencing coverage log ratios of genesMET, BRAF, CDK6, PIK3CA,MYC, CCND1,
and AR, quantiﬁed with the Vancouver panel in all 24 cfDNA samples. Bars highlighted in blue indicate that the gene was reported as ampliﬁed by
Guardant360 in that sample. Numbers above bars indicate the average gene copy numbers in ctDNA-shedding cancer cells that would produce the
observed coverage log ratio in the Vancouver panel data, correcting for presence of normal cfDNA (Patients and Methods). Chr, chromosome.
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somatic alterations falsely attributed to PC-derived ctDNA if
theWBC fraction were not analyzed.3 Because Guardant360
only analyzes cfDNA, the test cannot reject somatic cfDNA
mutations that are simultaneously detected in the blood
lineage. Consistent with these three points, a vast majority of
low AF mutations did not track with overall ctDNA fraction
and never rose to a signiﬁcant clonal fraction in longitudinal
sampling. Finally, earlier studies comparing commercial
ctDNA assays found large discordances in reported low AF
somatic mutations.10 Together, these results suggest that
Guardant360 should consider differential reporting of low
AF mutations, especially for mPC.
Somatic changes to the AR gene, including mutations,
ampliﬁcations, and rearrangements resulting in constitutive
activation, are primary drivers of resistance to systemic
therapies targeting the androgen axis in PC24 and are under
development as predictive cfDNA biomarkers.2,29,30 We
found near-perfect concordance between Guardant360
and the Vancouver panel for AR ampliﬁcations and hotspot
mutations, with the only limitation being that Guardant360
does not currently report intragenic AR rearrangements.
The Vancouver panel identiﬁed two patients with a poten-
tially ligand-independent AR in this cohort.
Guardant360 does not report germline alterations, somatic
copy number deletions, or large structural variants in the
DNA damage repair genes included in its panel. In mPC,
these classes of variants are common, especially across
BRCA2, and can have both prognostic and predictive
implications.31 Of particular relevance, biallelic BRCA2
defects can sensitize to PARP inhibitors, whereas deletions
overlapping the site of a pre-existing mutation (ie, so-called
reversion mutations) can drive PARP inhibitor resistance.
26,32 One quarter of the patients proﬁled here had bi-
ologically and clinically relevant DNA damage repair gene
alterations identiﬁed via sequencing with the Vancouver
panel. Because nongenomic specialists may not be aware
of the limits of commercial assays, we caution that negative
results from Guardant360 should be interpreted critically;
absence of reported somatic mutation in a gene does not
preclude other types of alterations (eg, somatic biallelic
BRCA2 deletion, rearrangement, or germline truncating
mutation).
In conclusion, we show that Guardant360 and targeted
ctDNA sequencing with a research assay (ie, the Vancouver
panel) are highly concordant for high AFmutations in mPC.
However, the Guardant360 test has potential limitations
in its reporting of indels, rearrangements, and germline
variants. Such variants are likely informative for guiding
patient treatment. In the future, optimal ctDNA commercial
assays for mPC should identify and report on all types of
somatic alterations, including deletions and rearrange-
ments; include mPC-speciﬁc genes, such as FOXA1,
SPOP, and ERG; and identify deleterious germline alter-
ations. Limitations of this study include the absence of
matched tissue to adjudicate discordances and the lack of
a standardized cohort to draw clinical outcome correlates.
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